Full Press Release Details
Melbourne (Australia) | 6 September 2023
Telix today announces presentations featuring the Company’s theranostic programs at the 36 th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 – 13 September 2023.
Further data from Telix’s completed pivotal Phase III ZIRCON study of TLX250-CDx ( 89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118 ) will be presented in on oral session on Sunday 10 September.
In addition, the congress program features the following Telix initiatives:
Dr Colin Hayward, Telix Chief Medical Officer, said, “We are pleased to be so well represented at this year’s EANM Annual Congress, with a sponsored symposium and abstracts accepted across Telix’s late-stage prostate and kidney cancer imaging and therapy programs. In addition, our innovations in AI and quantum computing for prostate cancer segmentation and characterisation will be featured in an oral presentation.
“Once again, we will be supporting the EANM Sanjiv Sam Gambhir Young Investigator Award, an exciting opportunity for a junior physician or scientist to further develop their career in radiopharmaceuticals. We look forward to seeing you at booth number 241 to discuss Telix’s industry leading theranostic pipeline and opportunities for collaboration.”
EANM presentation details are as follows:
Sponsored Symposium: Personalised diagnostics in urological cancers: the promise of nuclear medicine
Date & Time: Sunday, 10 September, 2023, 1:15 – 2:45 PM (CEST).
Session: Theranostics Track – Oncology & Theranostics Committee / EARL – Featured Session: Old but Novel Techniques
Title: 89 Zr-DFO-girentuximab PET/CT imaging for clear cell renal cell carcinoma – ZIRCON study results of diagnostic performance, including in very small lesions (oral presentation)
Date and Time: 10-Sep-23, 4:20 – 4:30 PM
Presenter: Clement Bailly, Nantes University Hospital, Nantes, FRANCE
Presentation ID: OP-194
Session: Cutting Edge Science Track – TROP Session: Segmentation and Denoising
Title: Using a 3-D UNet artificial intelligence model to segment PSMA-avid lesions in 68 Ga‑PSMA‑11 PET/CT images (top-rated oral presentation)
Date and Time: 10-Sep-23, 4:55 – 5:05 PM
Presenter: Simon Wail, Telix Pharmaceuticals, North Melbourne, AUSTRALIA
Presentation ID: OP-222
Session: M2M Track – TROP Session: TME and Therapy: Direct Targeting and Secondary Effects
Title: Evaluation of Therapeutic and Immunological Action of CAIX-Targeted Lutetium-177 Radionuclide Therapy Combined with Immune Checkpoint Inhibition (top-rated oral presentation)
Date and Time: 11-Sep-23, 10:15 – 10:25 AM
Presenter: Simone Kleinendorst, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS
Presentation ID: OP-358
Session: Clinical Oncology Track – TROP Session: Prostate Cancer Biochemical Recurrence
Title: The imaging characteristics of theranostic 99m Tc/ 188 Re-PSMA-GCK01 is equivalent to dedicated diagnostic 99m Tc-HYNIC-iPSMA in prostate cancer (top-rated oral presentation)
Date and Time: 11-Sep-23, 6:05 – 6:15 PM
Presenter: Eduards Mamlins, Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY
Presentation ID: OP-512
Session: e-Poster Presentations Session 10 – Oncology & Theranostics Committee: Haematological and Abdominal Malignancies / localised Treatments
Title: NOBLE (Nobody Left Behind) Registry: Initial Experience of [ 99m Tc]-HYNIC-iPSMA Imaging in the Detection of Prostate Cancer (oral e-poster presentation)
Date and Time: 12-Sep-23, 10:53 – 10:57 AM
Presenter: Fuad Novruzov, Department of Nuclear Medicine Azerbaijan National Centre of Oncology, Baku AZERBAIJAN
Presentation ID: EPS-206
Session: Cutting Edge Science Track – TROP Session: AI Methods and Applications
Title: Primary prostate characterization in PSMA-11 PET on real quantum computers (top-rated oral presentation)
Date and Time: 12-Sep-23, 3:00 – 3:10 PM
Presenter: Laszlo Papp, Medical University of Vienna, Vienna, AUSTRIA
Presentation ID: OP-706
Session: Clinical Oncology Track – TROP Session: Prostate Cancer Treatment
Title: ProstACT GLOBAL: A Phase 3 Study of 177 Lu-DOTA-rosopatamab (TLX591) With and Without the Best Standard of Care for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment with a Novel Androgen Axis Drug (top-rated oral presentation)
Date and Time: 12-Sep-23, 3:30 – 3:40 PM
Presenter: Neel Patel, Telix Pharmaceuticals, North Melbourne, AUSTRALIA
Presentation ID: OP-718
Session: D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control
Title: The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster)
Presenter: Yehia Omar, Misr Radiology Center, Cairo, EGYPT
Presentation ID: EP-0880
To read the full media release click here
[1] A collaboration with the Oncidium Foundation.